fbpx

Day

February 17, 2020
First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA, 13 February 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that the first patient has successfully been dosed in its pivotal phase 3...

News

How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020
A 60-year-old’s muscles aren’t old at all
23. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge